Panel Discussion: Uncovering Differentiated Targets, Exploring Editing in a Wider Range of Diseases & Identifying Patients Who Could Benefit from RNA Editing

• Identifying differentiated target sequences using human genomics data and AI

• Exploring editing ceilings and limitations of various targets

• Elucidating treatable diseases and identifying patients with the suitable genotype who could benefit from treatment

Speakers:

Andrew Fraley

Chief Innovation & Strategy Officer

Radar Therapeutics

Vincent DiGiacomo

Director, Therapeutic Innovation

Jorna Therapeutics

Jacob Borrajo

Founder & Chief Executive Officer

Amber Bio